Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036
Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.
How this was made
The 30-second read
Why it matters
The settlement removes immediate generic competition, supporting revenue forecasts and share price.
Market read
The news provides a clear catalyst for AUPH's stock, offering a short-term trading opportunity.
What to watch
Ongoing litigation with other generics could still erode market share despite the settlement.
Background
Aurinia's Lupkynis is its sole marketed product; patent protection is critical for revenue.
Ticker impact
Aurinia announced a patent settlement with Teva blocking a generic Lupkynis until 2036, causing a 7% share price rise.
Potential further upside if market digests the extended exclusivity timeline.
Extended patent protection is material for a single-product biotech; investors already reacted positively.
Market effects
Strengthens Lupus treatment niche, may pressure peers like GSK, Roche, AstraZeneca.
U.S. biotech sector sees a boost from exclusivity news.
Limited to biotech investors; no broad market effect.
Counterpoint
If Teva challenges the settlement or wins an appeal, the exclusivity could be shortened.
Key entities
- companyAurinia Pharmaceuticals
Biotech firm developing Lupkynis for lupus.
- companyTeva Pharmaceuticals
Generic drug manufacturer involved in the settlement.
